Cladribine ( 2-chlorodeoxyadenosine , CdA ) - @ - Antineoplastic
Drug Name:Cladribine ( 2-chlorodeoxyadenosine , CdA ) - @ - Antineoplastic
List Of Brands:
Indication Type Description:
Drug Interaction
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Patient Information
Pregnancy and lactation
Drug Interaction:
Reports not available
Indication:
Adverse Reaction:
Severe neutropenia 70% Fever 69% Infection 28%
Other adverse experiences reported frequently during the first 14 days after initiating treatment
Fatigue 45% Nausea 28% Rash 27% Headache 22% injection site infection 19%
Contra-Indications:
Hypersensitivity to the drug
Warnings-
Bone marrow suppression- including neutropenia, anemia, and thrombocytopenia
Nephrotoxicity /neurotoxicity - Mild neurotoxicites specially parathesis and dizziness, hav been reported rarely
Deaths- Of 196 HCl ( hairy cell leukemia ) entred in the trials, there were 8 deaths reported following treatment
Pregnancy- Use during pregnancy only if the benefit justifies the potential risk to the fetus
Lactation- Decide whether to discontinue nursing or discontinue the drug taking into account the importance of drug to the mother
Children- Safety and efficacy in children not established
Dosages/ Overdosage Etc:
Indication-
Hairy cell leukemia ( HCL )
Approved by FDA on February 26, 1993
Dosage-
Recommended dose- Single course given by continuous infusion for 7 consecutive days at a dose of .009mg/kg/day
Deviations from this dosage regimen are not adviced
Patient Information:
Pregnancy and lactation:
Pregnancy-
Use during pregnancy only if the benefit justifies the potential risk to the fetus
Lactation-
Decide whether to discontinue nursing or discontinue the drug taking into account the importance of drug to the mother
Children-
Safety and efficacy in children not established